The authors performed a randomized, double-blind, placebo-controlled trial to assess the tolerance and effects of chronic oral clonidine administration on the clinical status, exercise tolerance, and ventricular function of 10 male patients with chronic heart failure. Patients were given either oral clonidine (400 μg/day) or matching placebo for twelve weeks and then tapered off medication over a two-week period.
Results are summarized as follows: Profiles over time between groups were significantly different for resting heart rate (p = 0.0005), were different for arterial pressure (p=0.04), were different for left ventricular ejection fraction (p < 0.006), and were different for mean accumulated workload (p=0.076).
Exercise double product at 25 watts changed little in three patients and showed a decrease in 2 patients following six weeks of oral clonidine; after twelve weeks, it decreased in three patients, increased in 1, and changed little in another. After washout, double product returned toward baseline values. In the placebo groups, double product showed little change.
Resting of the heart by decreasing heart rate, systemic arterial blood pressure, and venous tone are thought by the authors to be major contributing factors to the observed beneficial effect of chronic oral clonidine in chronic heart failure.
Get full access to this article
View all access options for this article.
References
1.
Abboud FM, Schmid PG: Circulatory adjustments to heart failure. In: Heart Disease , ed. by Fischman A.New York, McGraw-Hill, 1979, p. 249-260.
2.
Chidsey CA, Harrison DC, Braunwald E.: Augmentation of the plasma norepinephrine response to exercise in patients with congestive heart failure. N Engl J Med267:650, 1962.
3.
Chidsey CA, Braunwald E., Morrow AG: Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure. Am J Med39:442, 1965.
4.
Dzau VJ, Colucci WS, Hollenberg NK, Williams GH: Relation of renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation63:645, 1981.
5.
Eckberg DL, Drabinsky M., Braunwald E.: Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med285:877, 1971.
6.
Francis GS, Goldsmith SR, Levine BT, et al: The neurohumoral axis in congestive heart failure. Ann Int Med101:370, 1984.
7.
Goldsmith SR , Francis GS, Cowley AW Jr, et al: Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol1:1385, 1983.
8.
Greenberg TT , Richmond WH, Stocking RA, et al: Impaired atrial receptor responses in dogs with heart failure due to tricuspid insufficiency and pulmonary artery stenosis. Circ Res32:424, 1973.
9.
Higgins CB, Vatner SF, Eckberg DL, Braunwald E.: Alterations in the baroreceptor reflex in conscious dogs with heart failure . J Clin Invest51:715, 1972.
10.
Thomas JA, Marks BH: Plasma norepinephrine in congestive heart failure. Am J Cardiol41:233, 1978.
11.
Captopril Multicenter Research Group: A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol2:755, 1983.
12.
Kramer BL, Massie BM, Topic N.: Controlled trial of captopril in chronic heart failure: A rest and exercise hemodynamic study. Circulation67:807, 1983.
13.
Swedberg K. , Hjalmarson A., Waagstein F., Wallentin I.: Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet1:1374, 1979.
14.
Swedberg K. , Hjalmarson A., Waagstein F., Wallentin I.: Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. Br Heart J44:117, 1980.
15.
Swedberg K. , Hjalmarson A., Waagstein F., Wallentin I.: Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy. Br Heart J44:133, 1980.
16.
Burch GE: The role of the central nervous system in chronic congestive heart failure . Am Heart J95:255, 1978.
17.
Aars H.: Effects of clonidine on aortic diameter and aortic baroreceptor activity. Eur J Pharmacol20:52, 1972.
18.
Ananekas SN : Jarrot B, Toscano M, Louis WJ: Pharmacokinetic and pharmacodynamic studies of oral clonidine in normotensive subjects. Eur J Clin Pharmacol23:1, 1982.
19.
Giles TD, Iteld BJ, Mauntner RK, et al: Short-term effects of intravenous clonidine in congestive heart failure. Clin Pharmacol Ther30:724, 1981.
20.
Hokfelt B., Hedeland H., Hansson B-G.: The effect of clonidine and penbutolol, respectively, on catecholamines in blood and urine, plasma renin activity and urinary aldosterone in hypertensive patients. Arch Int Pharmacodyn213:307, 1975.
21.
Kobinger W. : Uber den Wirkungsmechanismus einer neunen antihypertensiven substanz mit Imidazolinstruktur. Nauyn-Schmiedebergs Arch Pharmak U Exp Path258:48, 1967.
22.
Reid IA, MacDonald DM, Pachnis B., Ganong WF: Studies concerning the mechanism of suppression of renin secretion by clonidine . J Pharmacol Exp Ther192:713, 1975.
23.
Reid IA, Ahn JN, Trinh T., et al: Mechanism of suppression of vasopressin and adenocorticotropic hormone secretion by clonidine in anesthetized dogs. J Pharmacol Exp Ther229:1, 1984.
24.
Schmitt H., Schmitt H., Boissier JR, et al: Cardiovascular effects of 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (ST 155). Eur J Pharmacol2:340, 1968.
25.
Quiroz AC, Eilen SD, Sander GE, Giles TD: The effect of intravenous clonidine hydrochloride in the isolated forearm venous segment in heart failure. Chest83S:430S, 1983.
26.
Hermiller JB , Magorien RD, Leithe ME, et al: Clonidine in congestive heart failure: A vasodilator with negative inotropic effects. Am J Cardiol51:791, 1983.
27.
Motz W., Ippisch R., Strauer BE: The role of clonidine in hypertensive heart disease. Influence on myocardial contractility and left ventricular afterload. Chest83S:433, 1983.
28.
Franciosa JA, Goldsmith SR, Cohn JN: Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure. Am J Med69:559, 1980.
29.
Leier CV, Huss P., Magorien RD, Unverferth DV: Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure. Circulation67:817, 1983.
30.
Mason DT, Zelis R., Longhurst J., Lee G.: Cardiocirculatory responses to muscular exercise in congestive heart failure . Prog Cardiovasc Dis19:475, 1977.
31.
Rubin SA, Chatterjee K., Parmley WW: Metabolic assessment of exercise in chronic heart failure patients treated with short-term vasodilators. Circulation61:543, 1980.
32.
Pfisterer ME , Battler A., Swanson SM, et al: Reproducibility of ejection-fraction determinations by equilibrium radio-nuclide angiography in response to supine bicycle exercise: Concise communication. J Nucl Med20:491, 1979.
33.
Eugler R., Ray R., Higgins CB, et al: Clinical assessment and follow-up of functional capacity in patients with chronic congestive cardiomyopathy. Am J Cardiol49:1832, 1982.
34.
Higginbotham MB, Morris KG, Conn EH, et al: Determinants of variable exercise performance among patients with severe left ventricular dysfunction. Am J Cardiol51:52, 1983.
35.
Weber KT, Kinasewitz GT, Janicki JS, Fishman AP: Oxygen utilization and ventilation during exercise in patients with chronic cardiac failure. Circulation65:1213, 1982.
36.
Wilson JA, Martin JL, Ferraro N.: Impaired skeletal muscle nutritive flow during exercise in patients with congestive heart failure. Role of cardiac pump dysfunction as determined by the effect of dobutamine. Am J Cardiol53:1308, 1984.
37.
Kirlin PC, Grekin R., Smith CB, et al: Adrenergic inhibition in conestive heart failure: Hemodynamic, neuro-humoral and alpha receptor effects. J Am Coll Cardiol3:560, 1984 (abstr).
38.
Fowler MB, Bristow MR, Laser JA, et al: Beta blocker therapy in severe heart failure: Improvement related to beta-adrenergic receptors up regulation. Circulation70:111, 1984.
